相关实验视频

Updated: Jan 6, 2026

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

肌缩侧面硬化症和前性痴呆症具有不同的预诊断血液生物化学概况

Christos V Chalitsios¹, Jiali Gao¹, Carol A C Coupland^2,3

¹Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Annals of neurology

|October 30, 2025

概括

较高的LDL和总胆固醇与增加的肌缩性侧面硬化症 (ALS) 风险有关. 肌素和HbA1c可能与前性痴呆症 (FTD) 风险有关,这表明神经退行性疾病的潜在生物标志物.

科学领域:

神经科学是一个神经科学.
生物标志物生物标志物
流行病学流行病学

背景情况:

识别可改变的肌缩侧面硬化症 (ALS) 和前性痴呆症 (FTD) 的风险因素对于预防至关重要.
血液中的生物标志物,包括胆固醇,与ALS有不一致的关联,FTD的数据有限.

研究的目的:

调查各种血液生物标志物与发展ALS和FTD的风险的关联.
探索影响这些神经退行性疾病风险的潜在可改变因素.

主要方法:

一项基于人口的队列研究,利用英国初级保健记录 (QResearch) 和医院情节统计数据.
使用Cox比例危险模型,分析脂质特征 (LDL-C,HDL-C,总胆固醇),甘油三,肌,肌激酶,HbA1c和ALS/FTD风险之间的关联.
应用双样本门德尔随机化来检查基因预测的生物标志物协会.

主要成果:

增加的低密度脂蛋白胆固醇 (LDL-C) 和总胆固醇与增加的ALS风险线性相关.
较高的总胆固醇在60岁及以上的个体中与ALS风险有更强的关联.
观察到较高的肌水平与FTD风险之间的反向关联,由门德尔随机化支持.
在HbA1c水平和FTD风险之间发现了一个U形的关联.

结论:

LDL-C和总胆固醇可以提供有关早期疾病过程或ALS病因学的见解.
肌素和HbA1c可能是FTD风险的相关生物标志物.
需要对ALS和FTD的单一形式进行进一步的研究,以确定这些生物标志物是否可以为有针对性的预防或干预策略提供信息.

更多相关视频

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...